Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB 5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Next Previous
Trial Profile

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB 5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obexelimab (Primary)
  • Indications Immunoglobulin G4-related disease; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Xencor

Most Recent Events

  • 15 Nov 2023 Results of a PopPK model analysis from four clinical trials: a first-in-human, single-ascending dose study in healthy volunteers; 2) a multiple-ascending dose study in patients with RA; 3) an open-label study in patients with IgG4-RD; and 4) a PK and relative bioavailability study.
  • 09 Nov 2015 According to a Xencor media release, data from this study were presented at the American College of Rheumatology (ACR) 2015 Annual Meeting.
  • 26 Jun 2015 According to a Xencor media release, data from this study were presented at the European League Against Rheumatism (EULAR) 2015 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top